Related Experiment Videos
Clinical applications of IL-2
1Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Abstract:
Several years of clinical trials with IL-2, including modifications of dose and schedule and combinations with other biologic agents or chemotherapy, have shown much more limited anticancer activity for this agent than was anticipated from the preclinical studies. Even for its FDA-approved indication (metastatic renal cell carcinoma patients with good performance status), IL-2 probably benefits only a small subset of patients, and no prognostic factors have yet been identified to pinpoint these patients. In addition, clinical activity in patients with renal cell carcinoma treated with high-dose IL-2 is achieved at the expense of substantial acute toxicity. Nonetheless, the durable complete responses observed in a small percentage of patients with metastatic renal cell carcinoma and metastatic melanoma, and the potent immunomodulatory effects of IL-2, suggest that it may yet become an important anticancer agent, perhaps in association with active and adoptive immunotherapy. The agent also has shown potential for the treatment of infectious diseases and immunodeficiency states.
Insights
Interleukin-2 (IL-2) shows limited anticancer activity and significant toxicity in clinical trials, benefiting only a small subset of patients with metastatic renal cell carcinoma. Further research may optimize its use in immunotherapy for various diseases.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Preclinical studies suggested significant anticancer activity for Interleukin-2 (IL-2).
- Clinical trials revealed limited efficacy and substantial toxicity for IL-2 in cancer treatment.
- Current FDA-approved use in metastatic renal cell carcinoma benefits a small patient subset, with no identified prognostic factors.
Purpose of the Study:
- To evaluate the anticancer activity and toxicity of Interleukin-2 (IL-2) in clinical settings.
- To explore the potential of IL-2 in combination therapies and for other diseases.
Main Methods:
- Review of clinical trial data involving various doses, schedules, and combinations of IL-2.
- Analysis of patient responses and toxicities in metastatic renal cell carcinoma and melanoma.
- Assessment of IL-2's immunomodulatory effects.
Main Results:
- IL-2 demonstrated less anticancer activity than predicted from preclinical data.
- High-dose IL-2 for renal cell carcinoma resulted in significant acute toxicity.
- Durable complete responses were observed in a small percentage of patients with metastatic renal cell carcinoma and melanoma.
Conclusions:
- IL-2's clinical utility is limited by modest efficacy and significant toxicity.
- IL-2 may be valuable in immunotherapy, particularly in combination with other agents.
- IL-2 shows potential for treating infectious diseases and immunodeficiency states.